Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $45 price target.
July 18, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical and maintained a $45 price target.
The reiteration of a Neutral rating and maintenance of the $45 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100